Navigation Links
Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium
Date:1/12/2009

MONTVALE, N.J., Jan. 12 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) has completed enrollment of its BENEFICIAL study, a Phase 2 double-blind, placebo-controlled, randomized trial of the Company's compound alagebrium. The study is designed to measure the effect of alagebrium on exercise tolerance in patients with chronic systolic heart failure. In addition, the Company anticipates completing enrollment of its BREAK (Beginning a Randomized Evaluation of the A.G.E. [Advanced Glycation End Product] Breaker Alagebrium in Diastolic Heart Failure) study in the First Quarter of 2009. BREAK, a randomized, double-blind, placebo controlled study, evaluates whether alagebrium (200mg twice daily) can improve exercise tolerance, as measured by the 6-minute walk test, in patients diagnosed with diastolic heart failure.

"We are extremely pleased with the progress thus far in our clinical program for alagebrium," said Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista Therapeutics, developer of alagebrium. "Based on our dialogue with the FDA, we believe that exercise tolerance is an approvable regulatory endpoint, in patients with systolic or diastolic heart failure. Accordingly, we look forward to the timely completion of these studies which could provide proof of efficacy and a partial basis for drug approval."

About Alagebrium

Alagebrium is Synvista's clinical candidate for interfering with A.G.E.-related sclerosis and fibrosis of the heart, kidney and other tissues leading to heart failure, diabetic nephropathy and other disorders. It is a proprietary A.G.E. crosslink breaker that is designed to function unlike any previously developed pharmaceutical agents to reverse the disease states associated with age or diabetes-related stiffening of vessels, tissues and organs. Alagebrium has completed a series of
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Synvista Therapeutics to Present at the BIO InvestorForum 2007
2. Synvista Therapeutics to be Featured on Wallst.net
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
5. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
6. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
7. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
9. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
10. Synvista Therapeutics Posts Letter to Stockholders on Web Site
11. Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... (PRWEB) May 17, 2013 The paradigm ... complex biological systems that can help predict the adverse ... Dr. Sergey Stepaniants, Head of Computational Biology at the ... biology tools to ensure high-quality genomics when used as ... be applied to complex data sets to identify key ...
(Date:5/17/2013)... May 17, 2013 Rust removal is one ... non-metal home items could be damaged. To help rust contractors ... of its no-scrubbing rust remover it called Rusterizer. ... available with 10% discount. , My Cleaning Products explained that ... them or by staining them. The first one, it ...
(Date:5/17/2013)... Tooth decay is an epidemic in American children with 50% ... World Health Organization says that worldwide, 60–90% of ... are the long-term effects of this transmissible infection? , ... oral bacterial imbalance and serious systemic issues like heart disease. ... also 100% preventable? Answer: there has been no way to ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 ... Barbara A. Myers, CAE, to the newly created ... her new role, Myers will be responsible for ... and production strategies, advancing the Society’s Member-led and ... and continuing to refine organizational, membership and product ...
Breaking Biology Technology:Organic-Based Rust Remover Cuts Down Price by 10%, My Cleaning Products Details Mechanics How to Get the Discount 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2
... ... That Scientists Can Focus on Novel Research , ... (PRWEB) May 20, 2010 -- DNA2.0 , the leading gene synthesis ... in order to provide customers with a seamless experience from gene synthesis to protein expression ...
... surf in colder waters and keep warm for longer, ... wetsuit manufacturer, Spartan. Spartan specialise in wetsuits for ... measurement institute, to understand the science behind how wetsuits ... particular it wanted to improve its windsurfing wetsuits, which ...
... CAMBRIDGE, Massachusetts , May ... SHPGY ), the global specialty biopharmaceutical,company, today announced that ... from NORD. Shire was recognized for its efforts to ... enzyme replacement,therapy (ERT) for the treatment of Type 1 ...
Cached Biology Technology:DNA2.0 and Blue Sky Biotech Announce Strategic Alliance for Bundled Customer Experience From Gene Synthesis to Purified Protein 2DNA2.0 and Blue Sky Biotech Announce Strategic Alliance for Bundled Customer Experience From Gene Synthesis to Purified Protein 3A warmer future for watersports 2Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection) 2Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection) 3Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection) 4Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection) 5
(Date:5/16/2013)... Northwestern University scientists have shown a gene involved in ... proper function of the circadian clock. , In ... found the gene, called Ataxin-2, keeps the clock responsible ... the gene, the rhythm of the fruit fly,s sleep-wake ... schedule difficult for the fly. , The discovery ...
(Date:5/16/2013)... SPARTANBURG, S.C. , May 16, 2013 /PRNewswire/ ... film in combination with a custom thin film ...  the highest forensic quality roll image in the ... market today. Sherlock, an Appendix F Mobile ID ... provides a 95% reduction in size and weight ...
(Date:5/16/2013)... world are meeting next week in Toronto. The ... latest in research findings about the brain, the ... disorders that affect them., "Canada is a leader ... the best of neuroscience research done here and ... the Canadian Association for Neuroscience. He also reminds ...
Breaking Biology News(10 mins):Gene involved in neurodegeneration keeps clock running 27th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2
... 26, 2012  Medbox, Inc. (Pinksheets: MDBX) ( www.medboxinc.com ... for 2012. Through their subsidiary, ... dispensing and storage systems, which are designed to ... alternative medicine clinics and doctor,s offices. The systems ...
... , RICHLAND, Wash. The Department of Energy,s ... bringing a lab-developed technology that improves research sample ... Consortium announced today that PNNL is receiving a ... consortium is a nationwide network that encourages federal ...
... by the College of Agricultural Sciences, The Pennsylvania State University, ... for Abstract Submissions: 1 March 2012 -- The Society ... an abstract for presentation at the 45th SSR Annual Meeting ... Links to the following are to be found on ...
Cached Biology News:Medbox, Inc. Announces New Product Line for 2012 2PNNL recognized for technology transfer 2
...
Mouse monoclonal antibody raised against a partial recombinant AAAS. NCBI Entrez Gene ID = AAAS...
Rabbit polyclonal to MCP2 ( Abpromise for all tested applications). entrezGeneID: 6355 SwissProtID: P49873...
... and high speed homogeneous assay for the ... for screening of inhibitors in a high-throughput ... on a fluorescence superquenching technology that does ... universal platform provides flexibility for assaying any ...
Biology Products: